Nasdaq · CIK 0001653087
ALEC Alector, Inc.
Insider trading from SEC Form 4. Last filing 38 d ago. Close $2.08 on Oct 9, 2026, +82% from the 52-week low and -37% from the high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Alector, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Neil Lindsay Berkley CFO & Chief Business Officer sell | $78k 29,251 shares | -8% | +120% from low-24% from high | |
| 52Moderate | Arnon Rosenthal Chief Executive Officer sell | $193k 72,606 shares | -3% | +120% from low-24% from high | |
| 10Weak | Grace Wong-Sarad Principal Accounting Officer sell | $25k 9,446 shares | -8% | +139% from low-18% from high | |
| 10Weak | Grace Wong-Sarad Principal Accounting Officer sell | $2,650 1,000 shares | -1% | +163% from low-28% from high | |
| 51Moderate | Arnon Rosenthal Chief Executive Officer sell | $174k 81,864 shares | -3% | +144% from low-33% from high | |
| 30Weak | Grace Wong-Sarad Principal Accounting Officer sell | $17k 8,071 shares | -7% | +144% from low-33% from high | |
| 10Weak | Grace Wong-Sarad Principal Accounting Officer sell | $7,012 3,367 shares | -3% | +133% from low-36% from high | |
| 45Moderate | Neil Lindsay Berkley CFO & Chief Business Officer sell | $63k 29,649 shares | -8% | +144% from low-33% from high | |
| 10Weak | Grace Wong-Sarad Principal Accounting Officer sell | $10k 4,079 shares | -3% | +183% from low-23% from high | |
| 10Weak | Grace Wong-Sarad Principal Accounting Officer sell | $5,751 4,753 shares | -4% | +35% from low-63% from high | |
| 50Moderate | Arnon Rosenthal Chief Executive Officer sell | $117k 104,347 shares | -4% | +26% from low-66% from high | |
| 41Moderate | Sara Kenkare-Mitra President and Head of R&D sell | $47k 41,687 shares | -8% | +26% from low-66% from high | |
| 30Weak | Grace Wong-Sarad Principal Accounting Officer sell | $9,019 8,056 shares | -6% | +26% from low-66% from high | |
| 43Moderate | Neil Lindsay Berkley Chief Bus Ofcr & Interim CFO sell | $42k 37,261 shares | -9% | +26% from low-66% from high | |
| 51Moderate | Arnon Rosenthal Chief Executive Officer sell | $129k 51,562 shares | -2% | +187% from low-58% from high | |
| 42Moderate | Sara Kenkare-Mitra President and Head of R&D sell | $59k 23,638 shares | -4% | +187% from low-58% from high | |
| 36Weak | Neil Lindsay Berkley Principal Financial Officer sell | $40k 15,842 shares | -4% | +187% from low-58% from high | |
| 30Weak | Grace Wong-Sarad Principal Accounting Officer sell | $15k 5,910 shares | -5% | +187% from low-58% from high | |
| 21Weak | Paula Hammond director sell | $33k 14,000 shares | -16% | +161% from low-62% from high | |
| 0Weak | Kristine Yaffe director sell | $1,440 1,000 shares | -1% | +63% from low-76% from high | |
| 48Moderate | Arnon Rosenthal Chief Executive Officer sell | $70k 52,087 shares | -2% | +53% from low-78% from high | |
| 40Moderate | Sara Kenkare-Mitra President and Head of R&D sell | $32k 23,890 shares | -4% | +53% from low-78% from high | |
| 37Weak | Marc Grasso Chief Financial Officer sell | $22k 16,488 shares | -5% | +53% from low-78% from high | |
| 30Weak | Gary Romano Chief Medical Officer sell | $24k 16,306 shares | -5% | 0% from low-77% from high | |
| 47Moderate | Arnon Rosenthal Chief Executive Officer sell | $59k 40,330 shares | -2% | 0% from low-77% from high | |
| 41Moderate | Sara Kenkare-Mitra President and Head of R&D sell | $43k 29,073 shares | -5% | 0% from low-77% from high | |
| 42Moderate | Marc Grasso Chief Financial Officer sell | $27k 18,091 shares | -5% | 0% from low-77% from high | |
| 36Weak | Gary Romano Chief Medical Officer sell | $38k 14,892 shares | -4% | - | |
| 43Moderate | Sara Kenkare-Mitra President and Head of R&D sell | $67k 26,500 shares | -4% | - | |
| 51Moderate | Arnon Rosenthal Chief Executive Officer sell | $131k 52,172 shares | -2% | - | |
| 43Moderate | Marc Grasso Chief Financial Officer sell | $42k 16,489 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 29, 2024 | Arnon Rosenthal Officer, Director | 50,142 0.05% of outstanding | $130k | Dec 2, 2024 | $129k |
| Nov 29, 2024 | Marc Grasso Officer | 15,842 0.02% of outstanding | $41k | Dec 2, 2024 | $36k |
| Nov 29, 2024 | Sara Kenkare-Mitra Officer | 25,465 0.03% of outstanding | $66k | Dec 2, 2024 | $68k |
| Nov 29, 2024 | Gary Romano Officer | 14,306 0.01% of outstanding | $37k | Dec 2, 2024 | $41k |
Transactions
The last 61 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Neil Lindsay Berkley CFO & Chief Business Officer | SOpen-market sale Common Stock | -29,251 | $2.66 | $78k | 350,649 | 38 d ago |
| Sep 3, 2026 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -72,606 | $2.66 | $193k | 2,294,600 | 38 d ago |
| Sep 2, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -656 | $2.75 | $1,804 | 114,805 | 38 d ago |
| Sep 3, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock | -5,165 | $2.67 | $14k | 109,640 | 38 d ago |
| Sep 4, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -3,625 | $2.51 | $9,094 | 106,015 | 38 d ago |
| Mar 15, 2026 | Neil Lindsay Berkley CFO & Chief Business Officer | AGrant or award Common Stock | +54,600 | $0.00 | $0 | 399,260 | Mar 13, 2026 |
| Mar 13, 2026 | Arnon Rosenthal Chief Executive Officer | AGrant or award Common Stock | +116,246 | $0.00 | $0 | 2,454,422 | Mar 13, 2026 |
| Mar 10, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $2.65 | $2,650 | 106,465 | Mar 12, 2026 |
| Mar 3, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -3,367 | $2.08 | $7,012 | 107,465 | Mar 3, 2026 |
| Mar 2, 2026 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -81,864 | $2.12 | $174k | 2,338,176 | Mar 3, 2026 |
| Mar 2, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock | -8,071 | $2.12 | $17k | 110,832 | Mar 3, 2026 |
| Mar 2, 2026 | Neil Lindsay Berkley CFO & Chief Business Officer | SOpen-market sale Common Stock | -29,649 | $2.12 | $63k | 344,660 | Mar 3, 2026 |
| Feb 26, 2026 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -4,079 | $2.50 | $10k | 118,903 | Feb 26, 2026 |
| Dec 5, 2025 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock10b5-1 | -4,753 | $1.21 | $5,751 | 122,982 | Dec 8, 2025 |
| Dec 3, 2025 | Neil Lindsay Berkley Chief Bus Ofcr & Interim CFO | SOpen-market sale Common Stock | -37,261 | $1.12 | $42k | 374,309 | Dec 3, 2025 |
| Dec 3, 2025 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock | -8,056 | $1.12 | $9,019 | 127,735 | Dec 3, 2025 |
| Dec 3, 2025 | Sara Kenkare-Mitra President and Head of R&D | SOpen-market sale Common Stock | -41,687 | $1.12 | $47k | 501,652 | Dec 3, 2025 |
| Dec 3, 2025 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -104,347 | $1.12 | $117k | 2,420,040 | Dec 3, 2025 |
| Nov 10, 2025 | Arnon Rosenthal Chief Executive Officer | AGrant or award Common Stock | +174,167 | $0.00 | $0 | 2,524,387 | Nov 12, 2025 |
| Nov 10, 2025 | Grace Wong-Sarad Principal Accounting Officer | AGrant or award Common Stock | +32,343 | $0.00 | $0 | 135,791 | Nov 12, 2025 |
| Nov 10, 2025 | Neil Lindsay Berkley Chief Bus Ofcr & Interim CFO | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 411,570 | Nov 12, 2025 |
| Nov 10, 2025 | Grace Wong-Sarad Principal Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +48,535 | $0.00 | $0 | 48,535 | Nov 12, 2025 |
| Nov 10, 2025 | Neil Lindsay Berkley Chief Bus Ofcr & Interim CFO | AGrant or award Employee Stock Option (right to buy)derivative | +195,000 | $0.00 | $0 | 195,000 | Nov 12, 2025 |
| Nov 10, 2025 | Arnon Rosenthal Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +522,500 | $0.00 | $0 | 522,500 | Nov 12, 2025 |
| Sep 2, 2025 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -51,562 | $2.50 | $129k | 2,350,220 | Sep 4, 2025 |
| Sep 2, 2025 | Sara Kenkare-Mitra President and Head of R&D | SOpen-market sale Common Stock | -23,638 | $2.50 | $59k | 543,339 | Sep 4, 2025 |
| Sep 2, 2025 | Neil Lindsay Berkley Principal Financial Officer | SOpen-market sale Common Stock | -15,842 | $2.50 | $40k | 346,570 | Sep 4, 2025 |
| Sep 2, 2025 | Grace Wong-Sarad Principal Accounting Officer | SOpen-market sale Common Stock | -5,910 | $2.50 | $15k | 103,448 | Sep 4, 2025 |
| Aug 26, 2025 | Paula Hammond director | SOpen-market sale Common Stock10b5-1 | -14,000 | $2.36 | $33k | 74,909 | Aug 27, 2025 |
| Jul 1, 2025 | Neil Lindsay Berkley Principal Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Jul 1, 2025 |
| Jul 1, 2025 | Sara Kenkare-Mitra President and Head of R&D | AGrant or award Common Stock | +54,725 | $0.00 | $0 | 566,977 | Jul 1, 2025 |
| Jul 1, 2025 | Arnon Rosenthal Chief Executive Officer | AGrant or award Common Stock | +137,125 | $0.00 | $0 | 2,551,782 | Jul 1, 2025 |
| Jul 1, 2025 | Sara Kenkare-Mitra President and Head of R&D | AGrant or award Employee Stock Option (right to buy)derivative | +18,250 | $0.00 | $0 | 18,250 | Jul 1, 2025 |
| Jul 1, 2025 | Arnon Rosenthal Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +45,700 | $0.00 | $0 | 45,700 | Jul 1, 2025 |
| Jun 20, 2025 | Kristine Yaffe director | SOpen-market sale Common Stock10b5-1 | -1,000 | $1.44 | $1,440 | 95,409 | Jun 23, 2025 |
| Jun 11, 2025 | Mark Altmeyer director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 69,950 | Jun 12, 2025 |
| Jun 11, 2025 | Paula Hammond director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 88,909 | Jun 12, 2025 |
| Jun 11, 2025 | Kristine Yaffe director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 96,409 | Jun 12, 2025 |
| Jun 11, 2025 | Elizabeth A. Garofalo director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 89,950 | Jun 12, 2025 |
| Jun 11, 2025 | Richard H Scheller director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 95,366 | Jun 12, 2025 |
| Jun 11, 2025 | Louis J Lavigne Jr director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 99,409 | Jun 12, 2025 |
| Jun 11, 2025 | Errol B Desouza director | AGrant or award Common Stock | +28,700 | $0.00 | $0 | 69,950 | Jun 12, 2025 |
| Jun 11, 2025 | Richard H Scheller director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Errol B Desouza director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Elizabeth A. Garofalo director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Kristine Yaffe director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Mark Altmeyer director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Paula Hammond director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 11, 2025 | Louis J Lavigne Jr director | AGrant or award Stock Option (right to buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Jun 12, 2025 |
| Jun 2, 2025 | Sara Kenkare-Mitra President and Head of R&D | SOpen-market sale Common Stock | -23,890 | $1.34 | $32k | 512,252 | Jun 4, 2025 |
| Jun 2, 2025 | Marc Grasso Chief Financial Officer | SOpen-market sale Common Stock | -16,488 | $1.34 | $22k | 296,072 | Jun 4, 2025 |
| Jun 2, 2025 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -52,087 | $1.34 | $70k | 2,414,657 | Jun 4, 2025 |
| May 2, 2025 | Richard H Scheller director | AGrant or award Common Stock | +15,833 | $0.00 | $0 | 66,666 | May 2, 2025 |
| Mar 3, 2025 | Gary Romano Chief Medical Officer | SOpen-market sale Common Stock | -16,306 | $1.47 | $24k | 332,977 | Mar 5, 2025 |
| Mar 3, 2025 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -40,330 | $1.47 | $59k | 2,466,744 | Mar 5, 2025 |
| Mar 3, 2025 | Sara Kenkare-Mitra President and Head of R&D | SOpen-market sale Common Stock | -29,073 | $1.47 | $43k | 536,142 | Mar 5, 2025 |
| Mar 3, 2025 | Marc Grasso Chief Financial Officer | SOpen-market sale Common Stock | -18,091 | $1.47 | $27k | 312,560 | Mar 5, 2025 |
| Dec 2, 2024 | Gary Romano Chief Medical Officer | SOpen-market sale Common Stock | -14,892 | $2.52 | $38k | 349,283 | Dec 3, 2024 |
| Dec 2, 2024 | Sara Kenkare-Mitra President and Head of R&D | SOpen-market sale Common Stock | -26,500 | $2.52 | $67k | 565,215 | Dec 3, 2024 |
| Dec 2, 2024 | Arnon Rosenthal Chief Executive Officer | SOpen-market sale Common Stock | -52,172 | $2.52 | $131k | 2,507,074 | Dec 3, 2024 |
| Dec 2, 2024 | Marc Grasso Chief Financial Officer | SOpen-market sale Common Stock | -16,489 | $2.52 | $42k | 330,651 | Dec 3, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Mark Altmeyerdirector
- Neil Lindsay BerkleyCFO & Chief Business Officer
- Errol B Desouzadirector
- Elizabeth A. Garofalodirector
- Marc GrassoChief Financial Officer
- Paula Hammonddirector
- Sara Kenkare-MitraPresident and Head of R&D
- Louis J Lavigne Jrdirector
- Gary RomanoChief Medical Officer
- Arnon RosenthalChief Executive Officer
- Richard H Schellerdirector
- Grace Wong-SaradPrincipal Accounting Officer
- Kristine Yaffedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.